One of Eli Lilly’s most promising new obesity drugs helped patients lose about 28.7% of their body weight while also reducing pain associated with knee osteoarthritis. The drug giant’s LLY stock was ...

FDA chief's office said it wants to cut the filing review from 60 days to one week The office said it may cut those reviews to two or three weeks based on complexity The agency could decide on Lilly's ...

Move over Ozempic, Wegovy, Mounjaro and Zepbound — Eli Lilly says another contender may be on the way. The pharmaceutical giant announced encouraging results from a Phase 3 clinical trial of its ...

The long history of underground drug use abounds with secret societies—colorful cliques of like-minded individuals surreptitiously experimenting with newfangled compounds in an effort to understand ...

Dec 12 (Reuters) - Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation ‌of Eli Lilly's experimental weight‑loss pill, after the company ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Eli Lilly announced plans to invest more than $6 billion to build a manufacturing plant in Huntsville, Alabama, focused on weight loss medications and other pharmaceutical ingredients. The site will ...

The pharmaceutical giant Eli Lilly has once again raised the bar in the highly competitive obesity treatment market. New clinical trial data for its experimental drug Retatrutid has delivered results ...

How do you swear in Danish? Our AI chatbots are much too polite to help us out here, but we suspect you would have heard them all echoing outside the offices of Novo Nordisk yesterday. Eli Lilly, its ...

(REUTERS) — Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a late-stage trial, outperforming its blockbuster drug Zepbound and ...

Eli Lilly (LLY) shares spiked ~3% on Thursday after the obesity drugmaker posted Phase 3 data showing its next-gen therapy retatrutide can generate up to 24% of weight loss, a “best-in-class" efficacy ...